Cargando…

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common subtype of renal cell carcinoma (RCC), and is frequently accompanied by the genetic features of von Hippel–Lindau (VHL) loss. VHL loss increases the expression of hypoxia-inducible factors (HIFs) and their targets, including epidermal growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lai, Yongchang, Zhao, Zhijian, Zeng, Tao, Liang, Xiongfa, Chen, Dong, Duan, Xiaolu, Zeng, Guohua, Wu, Wenqi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838927/ https://www.ncbi.nlm.nih.gov/pubmed/29527128 http://dx.doi.org/10.1186/s12935-018-0530-2

Ejemplares similares

Connexin43 is associated with the progression of clear cell renal carcinoma and is regulated by tangeretin to sygergize with tyrosine kinase inhibitors
por: Lai, Yongchang, et al.
Publicado: (2023)

The value of cytoreductive nephrectomy on the survival of metastatic renal carcinoma patients based on the number of site-specific metastases
por: Zhao, Zhijian, et al.
Publicado: (2019)

Cell death-related molecules and biomarkers for renal cell carcinoma targeted therapy
por: Lai, Yongchang, et al.
Publicado: (2019)

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018)

Abnormal Crosstalk between Endothelial Cells and Podocytes Mediates Tyrosine Kinase Inhibitor (TKI)-Induced Nephrotoxicity
por: Gu, Xiaoying, et al.
Publicado: (2021)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Use of the ureteral access sheath during ureteroscopy: A systematic review and meta-analysis
por: Huang, Jian, et al.
Publicado: (2018)

Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis
por: Bracarda, S, et al.
Publicado: (2012)

PD-L1 Upregulation by the mTOR Pathway in VEGFR-TKI–Resistant Metastatic Clear Cell Renal Cell Carcinoma
por: Jeong, Se Un, et al.
Publicado: (2023)

Partial versus radical nephrectomy for T1b-2N0M0 renal tumors: A propensity score matching study based on the SEER database
por: Zhang, Mengping, et al.
Publicado: (2018)

MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma
por: Kinget, Lisa, et al.
Publicado: (2021)

Identifying the novel key genes in renal cell carcinoma by bioinformatics analysis and cell experiments
por: Chen, Yeda, et al.
Publicado: (2020)

Integrative Analysis of miRNA and mRNA Expression Profiles in Calcium Oxalate Nephrolithiasis Rat Model
por: Lan, Chuangxin, et al.
Publicado: (2017)

LncRNA-miRNA-mRNA expression variation profile in the urine of calcium oxalate stone patients
por: Liang, Xiongfa, et al.
Publicado: (2019)

VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
por: Amano, Hideki, et al.
Publicado: (2021)

Correction: Identifying the novel key genes in renal cell carcinoma by bioinformatics analysis and cell experiments
por: Chen, Yeda, et al.
Publicado: (2022)

Integrin β(3) Crosstalk with VEGFR Accommodating Tyrosine Phosphorylation as a Regulatory Switch
por: West, Xiaoxia Z., et al.
Publicado: (2012)

Study of Cathepsin B inhibition in VEGFR TKI treated human renal cell carcinoma xenografts
por: Chen, Chun-Hau, et al.
Publicado: (2019)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
por: Kwok, Christopher, et al.
Publicado: (2023)

Extended therapy breaks from VEGFR TKI therapy in renal cell carcinoma: Sometimes less is more
por: Zahoor, Haris, et al.
Publicado: (2017)

Clinical impact of early response to first‐line VEGFR‐TKI in patients with metastatic renal cell carcinoma on survival: A multi‐institutional retrospective study
por: Sobu, Ryuta, et al.
Publicado: (2022)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma
por: Wang, Xiaoen, et al.
Publicado: (2016)

Ponatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
por: Zeng, Peng, et al.
Publicado: (2020)

Development of Second-Generation VEGFR Tyrosine Kinase Inhibitors: Current Status
por: Bhargava, Pankaj, et al.
Publicado: (2011)

Nuclear localization of the tyrosine kinase BMX mediates VEGFR2 expression
por: Liu, Tingting, et al.
Publicado: (2019)

Reviewing Treatment Options for Advanced Renal Cell Carcinoma: Is There Still a Place for Tyrosine Kinase Inhibitor (TKI) Monotherapy?
por: Fontes-Sousa, Mário, et al.
Publicado: (2022)

Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer
por: Kang, Soyoung, et al.
Publicado: (2023)

Clinical and molecular feature-based nomogram model for predicting benefit from bevacizumab combined with first-generation EGFR-tyrosine kinase inhibitor (TKI) in EGFR-mutant advanced NSCLC
por: Zhang, Yongchang, et al.
Publicado: (2021)

PET imaging with radiolabeled antibodies and tyrosine kinase inhibitors: immuno-PET and TKI-PET
por: van Dongen, Guus A. M. S., et al.
Publicado: (2012)

Monitoring the Response to Tyrosine Kinase Inhibitor (TKI) Treatment in Chronic Myeloid Leukemia (CML)
por: Haznedaroglu, Ibrahim C.
Publicado: (2014)

BCR-ABL tyrosine kinase inhibitor (TKI)-induced nephropathy: An under-recognized phenomenon
por: Stanchina, Michele, et al.
Publicado: (2020)

ZD6474 – a novel inhibitor of VEGFR and EGFR tyrosine kinase activity
por: Ryan, A J, et al.
Publicado: (2005)

Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody
por: Huang, Jiwei, et al.
Publicado: (2021)

Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models
por: Dev, I K, et al.
Publicado: (2004)

The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors
por: Zhang, Haoran, et al.
Publicado: (2020)

Randomised controlled trial of first-line tyrosine-kinase inhibitor (TKI) versus intercalated TKI with chemotherapy for EGFR-mutated nonsmall cell lung cancer
por: Gijtenbeek, Rolof G.P., et al.
Publicado: (2022)

The VEGFR/PDGFR tyrosine kinase inhibitor, ABT-869, blocks necroptosis by targeting RIPK1 kinase
por: Pierotti, Catia L., et al.
Publicado: (2023)

Micropercutaneous nephrolithotomy versus retrograde intrarenal surgery in the treatment of renal stones: A systematic review and meta-analysis
por: Li, Xiaohang, et al.
Publicado: (2018)

Levels of circulating CD45(dim)CD34(+)VEGFR2(+) progenitor cells correlate with outcome in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitors
por: Farace, F, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_lq33s9ftp4m8euqil61peuornn